Beneficial effects of N-acetylcysteine on systemic lupus erythematosus disease activityand its associated complications
Phase 2
- Conditions
- Systemic Lupus erythromatosis.Systemic lupus erythematosus (SLE)
- Registration Number
- IRCT20181030041500N2
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Age more than 16
Having lupus
History of using prednisone, azathioprine, mycophenolate mofetil
Satisfaction with participation in the study
Exclusion Criteria
Pregnant or lactating patients
Having any disease at the same time
History of chronic infections
Bronchiectasis
Infection in last month
History of severe infections or frequent infections
Smoking
Patients with excessive use of antioxidants (daily and without Prescription) and acetaminophen
Acute SLE flares threatening vital organs
People in need of treatment with intravenous cyclophosphamide
Patients who are candidates for biological drugs rituximab, abatacept
Dissatisfaction for participation in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The activity of lupus disease. Timepoint: At the beginning of study and 3 months later. Method of measurement: SLEDAI and BILAG scoring protocol.
- Secondary Outcome Measures
Name Time Method